Construction and Preclinical Evaluation of a 124/131I-Labeled Radiotracer for the Detection of Mesothelin-Overexpressing Cancer-Reference-Cited by-同舟云学术

Construction and Preclinical Evaluation of a 124/131I-Labeled Radiotracer for the Detection of Mesothelin-Overexpressing Cancer

Published:2020-05-01 Issue:6 Volume:17 Page:1875-1883
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Wang Xudong¹,Wang Feng²,Han Jintao¹,Yang Zhi²^ORCID,Zhu Hua²^ORCID,Yang Gen¹

Affiliation:

1. State Key Laboratory of Nuclear Physics and Technology, School of Physics, Peking University, Beijing 100871, China

2. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China

Funder

National Natural Science Foundation of China

Beijing Nova Program

Beijing Municipal Administration of Hospitals

Beijing Excellent Talents Funding

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.9b01281

Reference34 articles.

1. Radioimmunoimaging with Longer-Lived Positron-Emitting Radionuclides: Potentials and Challenges

2. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma

3. Highly Specific PET Imaging of Prostate Tumors in Mice with an Iodine-124-Labeled Antibody Fragment That Targets Phosphatidylserine

4. Molecular Imaging of Immunotherapy Targets in Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Construction of a ¹²⁴I-Labeled Specific Antibody for the Noninvasive Detection of Mesothelin-Overexpressing Tumors;Molecular Pharmaceutics;2022-07-29

2. China’s radiopharmaceuticals on expressway: 2014–2021;Radiochimica Acta;2022-04-21